Short Interest in Opus Genetics Drops by 30.7%

Opus Genetics sees significant decline in short positions as stock price rises

Published on Feb. 14, 2026

Got story updates? Submit your updates here. ›

Opus Genetics, Inc. (NASDAQ:IRD) saw a large decrease in short interest in January, with the number of shares sold short dropping by 30.7% to 664,201 shares. This decline in short positions comes as the stock price has risen, with the company's shares trading around $3.64 as of the latest report.

Why it matters

The drop in short interest suggests increased investor confidence in Opus Genetics, a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for refractive and retinal eye disorders. A decline in short positions can indicate that more investors are taking long positions and believe the stock is undervalued.

The details

According to the report, as of January 30th, there was short interest totaling 664,201 shares in Opus Genetics, a decrease of 30.7% from the January 15th total of 957,806 shares. Based on the company's average daily trading volume of 924,259 shares, the current short-interest ratio is 0.7 days, meaning it would take less than a day for short sellers to cover their positions.

  • As of January 30th, there was short interest totaling 664,201 shares.
  • This represents a 30.7% decrease from the January 15th total of 957,806 shares.

The players

Opus Genetics, Inc.

A clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for refractive and retinal eye disorders.

Got photos? Submit your photos here. ›

The takeaway

The significant decline in short interest in Opus Genetics suggests growing investor confidence in the company's prospects, as the stock price has risen. This could indicate that the market believes the company's pipeline of ophthalmic treatments is undervalued and has potential for future growth.